18th July 2022 | Pharma Updates

PharmaState Updates – Latest Pharma Happenings

Health Minister directs NMC to inquire into doctor involvements with pharma following Micro Labs IT Raid

The government is now going to begin a separate and special inquiry to uncover the unethical links that the pharmaceutical firm had with the doctors as a result of the recent IT raids on the company that made Dolo 650, Micro Labs.

AIOCD seeks Centre involvementto haltthe operation of e-pharmacies

All India Organization of Chemists and Druggists (AIOCD) has urged the Union Health and Family Welfare Ministry to stop operating e-pharmacies and expressed grave concern over the sale of counterfeit drugs through online pharmacies, endangering public health.

Draft New Drugs Bill adheres to certain MD Rules 2017 guidelines: MTaI chairman

New Drugs, Medical Devices and Cosmetics Bill 2022, as per the Medical Technology Association of India (MTaI), an association of research-based medical technology businesses, adheres to several of the Medical Devices Rules 2017’s guiding principles.

India preparing to take bigger piece of $80 billion medical tourism sector

The Government of India (GoI) has chosen a niche: it is currently concentrating more on medical tourism, a market with a global market value of $60-80 billion. This number is based on the assumption that 14 million medical tourists cross international boundaries each year.

Amazon focusing on breast and skin cancer vaccines and ready for Phase 1 trials.

The world’s largest e-commerce company Amazon is working with the Fred Hutchinson Cancer Research Center to create a cancer vaccine as well as melanoma and breast cancer vaccinations.

GSK sets off a consumer health company with potential value of $57 billion

GSK will spin off Haleon, a consumer health company, for up to 48 billion pounds ($57 billion). With products including Sensodyne toothpaste and Advil medicines, Haleon is the largest global consumer health firm and includes assets formerly owned by Novartis, Pfizer, and GSK.

Novo Nordisk and Eli Lilly are poised to divide an obesity market worth $50 billion by 2030

Drugmakers like Eli Lilly and Novo Nordisk are preparing to open up a global obesity market that may be worth more than $50 billion by the end of the decade, despite ongoing issues with reimbursement and education.